Latest Glioma Stories
Results Continue to Show Safety and Promising Survival; Program to Advance into a Randomized, Controlled Trial SAN DIEGO, April 10, 2014 /PRNewswire/ --
VAL-083 therapy is well tolerated to date; dose limiting toxicity has not been reached after fifth cohort (20mg/m2) VANCOUVER, British Columbia and MENLO PARK, Calif., April 9, 2014 /PRNewswire/
Comprehensive genomic analysis of low-grade brain tumors sorts them into three categories, one of which has the molecular hallmarks and shortened survival of glioblastoma multiforme, the most lethal of brain tumors.
Researchers studying a rare, always fatal brain tumor in children have found several molecular alterations that drive the cancer.
Cancer patients with secondary brain tumors need information on diagnosis/treatment. Chicago, IL (PRWEB) March 19, 2014 As more effective cancer diagnostics
Intravenous Delivery Is An Important Advancement in the Development of Toca 511, Creates Opportunity For Use In Additional Cancer Indications SAN DIEGO, March 11, 2014 /PRNewswire/
DCVax-L Is First Product of Its Kind to Receive Hospital Exemption from German Regulator BETHESDA, Md., March 10, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology
Cedars-Sinai animal study may lead to human trial of experimental, compact intraoperative device to aid removal of malignant brain tumors
Interim clinical data to be presented at American Association of Cancer Research (AACR) Annual Meeting on April 9, 2014 VANCOUVER, British Columbia and MENLO PARK, Calif., Feb.
The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that few die from the tumor as adults.